Claims

1. A pharmaceutical composition comprising (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine or a pharmaceutically acceptable salt thereof, and one or more active pharmaceutical ingredients selected from BCL2 inhibitors, BET inhibitors, EZH2 inhibitors, Chk inhibitors, bendamustine, temozolomide, Aurora kinase inhibitors, infrigratinib (BGJ398), lapatinib and pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients.

2. Use of (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine or a pharmaceutically acceptable salt thereof, and one or more active pharmaceutical ingredients selected from BCL2 inhibitors, BET inhibitors, EZH2 inhibitors, Chk inhibitors, bendamustine, temozolomide, Aurora kinase inhibitors, infrigratinib (BGJ398), lapatinib and pharmaceutically acceptable salts thereof, for the preparation of a medicament for the treatment of a neoplastic disease.

3. Use of (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a neoplastic disease, wherein (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine or a pharmaceutically acceptable salt thereof is to be administered in combination with one or more active pharmaceutical ingredients selected from BCL2 inhibitors, BET inhibitors, EZH2 inhibitors, Chk inhibitors, bendamustine, temozolomide, Aurora kinase inhibitors, infrigratinib (BGJ398), lapatinib and pharmaceutically acceptable salts thereof.

4. Use of one or more active pharmaceutical ingredients selected from BCL2 inhibitors, BET inhibitors, EZH2 inhibitors, Chk inhibitors, bendamustine, temozolomide, Aurora kinase inhibitors, infrigratinib (BGJ398), lapatinib and pharmaceutically acceptable salts thereof, for the preparation of a medicament for the treatment of a neoplastic disease, wherein one or more active pharmaceutical ingredients selected from BCL2 inhibitors, BET inhibitors, EZH2 inhibitors, Chk inhibitors, bendamustine, temozolomide, Aurora kinase inhibitors, infrigratinib (BGJ398), lapatinib and pharmaceutically acceptable salts thereof are to be administered in combination with (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine or a pharmaceutically acceptable salt thereof.

5. The use according to any one of claims 2 to 4, wherein the active pharmaceutical ingredient is a BCL2 inhibitor or a pharmaceutically acceptable salt thereof.

6. The use according to any one of claims 2 to 4, wherein the active pharmaceutical ingredient is a BCL2 inhibitor selected from the list of venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, Obatoclax, TW-37 and a pharmaceutically acceptable salt thereof.

7. The use according to any one of claims 2 to 4, wherein the active pharmaceutical ingredient is a BCL2 inhibitor selected from the list of venetoclax (ABT-199), navitoclax (ABT-263), and a pharmaceutically acceptable salt thereof.

8. The use according to any one of claims 2 to 7, wherein (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine bis-hydrochloride is used.

9. The use of any one of claims 2 to 8, wherein the neoplastic disease is a cancer.

10. The use of any one of claims 2 to 8, wherein the neoplastic disease is selected from breast cancer, prostate cancer, cervical cancer, ovarian cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung cancer, kidney cancer, melanoma and sarcomas.

11. The use of any one of claims 2 to 8, wherein the neoplastic disease is a solid tumor.

12. The use of any one of claims 2 to 8, wherein the neoplastic disease is lung cancer or neuroendocrine cancer.

13. The use of any one of claims 2 to 8, wherein the neoplastic disease is lung cancer.

14. The use of any one of claims 2 to 8, wherein the neoplastic disease is small cell lung cancer (SCLC).

15. The use of any one of claims 2 to 8, wherein the neoplastic disease is a hematological malignancy.

16. The use of any one of claims 2 to 8, wherein the neoplastic disease is acute myeloid leukemia (AML).